A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 994
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : RTX
Long Form : rituximab
No. Year Title Co-occurring Abbreviation
2021 A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. CYC, ILD, NT-proBNP, SSc
2021 A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: A meta-analysis. MD, MOG
2021 A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab. IgG4-RD, RI
2021 A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues. mAbs, MS, OCR, OFA, PPMS, RMS, UB
2021 A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome. eGFR, PN, RNS, SN
2021 A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy. CYC, IBCDT, IQR, LN, MMF
2021 Acute hepatitis E in an immunocompromised patient with seropositive rheumatoid arthritis on rituximab and long-term methotrexate. HEV, MTX, RA
2021 Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. anti-MDA5, DM, HRCT, MDA5, RP-ILD
2021 Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases. ADA, IRR, PD, PK
10  2021 Antisynthetase Syndrome-Associated Interstitial Lung Disease: Monitoring of Immunosuppressive Treatment Effects by Chest Computed Tomography. ASyS, ASyS-ILD, HRCT, ILD, PFT
11  2021 Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. ABA, DMARDs, IL-6i, JAKi, RA
12  2021 Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis. BAR, bDMARDs, ETN, GOL, JAKi, RA, TCZ, TOF
13  2021 Can we predict if patients will require more than one cycle of rituximab? IS, SLE
14  2021 Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab. AIBD, SARS
15  2021 Case Report: Repeated Low-Dose Rituximab Treatment Is Effective in Relapsing Neuro Behçet's Disease. BD, NBD
16  2021 Combination of ultra-low dose rituximab and low dose tacrolimus versus tacrolimus alone in the treatment of non-responsive idiopathic membranous nephropathy: a Chinese retrospective cohort study. eGFR, IMN, RTX/TAC, TAC, TAC
17  2021 Comparative analysis of immunosuppressive therapies for myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: a cohort study. ARR, IST, MMF, MOG-ON
18  2021 Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis. AAV, CI
19  2021 Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength. OBI, OFA
20  2021 Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis. CI, FSGS, MCD, OR
21  2021 Correlation of anti-γ/ε nicotinic acetylcholine receptor antibody levels with anti-desmoglein 1,3 antibody levels and disease severity in pemphigus vulgaris. Abs, AChR, Dsg, PDAI, PV
22  2021 Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. ASPN, CARRA, CYC, LN, MMF
23  2021 Dose-dependent Pharmacological Response to Rituximab in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. AAV, ANCA
24  2021 Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. ABA, bDMARD, RA, TCZ, TNFi
25  2021 Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis. CLB, GC, ICER, IMN, LEF, MMF, RCTs, SUCRA, TAC
26  2021 Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. ABA, CTD, ILD, TCZ
27  2021 Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis. AChR, MG, MGFA-PIS
28  2021 Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. CI, CR, FR, FSGS, MCD, NR, NS, PR, SD
29  2021 Efficacy and safety of rituximab in autoimmune pancreatitis type 1: our experiences and systematic review of the literature. AIP, GC
30  2021 Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis. PUK, RA, RV
31  2021 Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. ILD, RA
32  2021 Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis. RCTs, SSc
33  2021 Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis. AEs, AQP4-Ab, EDSS, ELISA, NMO-ON
34  2021 Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis. ARR, EDSS, MeSH, NMO, NMOSD
35  2021 Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment. BCVA, EDI-OCT, SFCT, VKH
36  2021 Evaluation of Hepatitis B screening and reactivation in patients receiving rituximab containing chemotherapy: A single-centre study. HBsAg, HBV
37  2021 Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. AEs, ARR, CDP, CLA, IPTW, MRI, NTZ, OCR, PML, PS, RRMS
38  2021 Flare of a mixed cryoglobulinaemic vasculitis after obinutuzumab infusion. CV, mAb, OBZ, SS
39  2021 Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients. AAV, ANCA, ASC, HSFC, MRA, PBMCs, PBs, PC, Pre-GC
40  2021 Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus? HCQ, SLE
41  2021 Immune checkpoint markers and anti-CD20-mediated NK cell activation. OBZ, TIGIT, TIM3
42  2021 Impaired Kidney Function Associated with Increased Risk of Side Effects in Patients with Small Vessel Vasculitis Treated with Rituximab as an Induction Therapy. SVV
43  2021 Importance of antibody isotypes in antitumor immunity by monocytes and complement using human-immune tumor models. mAbs
44  2021 Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis. CAS, GO, SMD, TRAb
45  2021 Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis. CTs, FVC, ILD, ROBINS-I, SR, SSc
46  2021 Is the fluorescence optical imaging (FOI) able to discriminate between rheumatoid arthritis patients with and without need of rituximab retherapy? A cohort study. AUC, FOI, PVM, RA
47  2021 Laryngeal mucous membrane pemphigoid serves as a prognostic factor for poor response to treatment with rituximab. CR, MMP
48  2021 Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. HBV, prHBV
49  2021 Low-dose rituximab protocol in rheumatoid arthritis-outcome and economic impact. cDMARDs
50  2021 Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder. ARR, AZA, EDSS, mIVIG, MMF, MOGAD, SMD
51  2021 Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review. ANCA, EGPA, IVCY, MPZ
52  2021 Noninfectious, Severe Cryoglobulinemic Vasculitis with Renal Involvement - Safety and Efficacy of Long-Term Treatment with Rituximab. CV, RF, SAEs
53  2021 Novel Therapies for ANCA-associated Vasculitis. ANCA, CYC, EGPA, GC, GPA, MPA
54  2021 Obinutuzumab in Kidney Transplantation: Effect on B-cell Counts and Crossmatch Tests. CDC, OBZ
55  2021 Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed. MCTD
56  2021 Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder. NMOSD
57  2021 Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. ABA, bDMARD, MOAs, RA, TCZ, TNFi
58  2021 Risk of Diverticulitis and Gastrointestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab or Abatacept. ABA, GIP, HR, TCZ
59  2021 Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases. anti-TNF, COVID-19, IRD
60  2021 Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus. DSGs
61  2021 Rituximab and Mepolizumab Combination Therapy for Glucocorticoid-Resistant Myocarditis Related to Eosinophilic Granulomatosis With Polyangiitis. ANCA, EGPA, MPZ
62  2021 Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis. AHSCT, SSc
63  2021 Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease. AAV, ANCA, CI, IgG, OR, SLE
64  2021 Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies. EGPA
65  2021 Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. CR, KT, PP, PR
66  2021 Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review. cDMARDs, EF
67  2021 Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: A systematic review and meta-analysis. CI, IMN, ISTs, NS, OR
68  2021 Rituximab for the treatment of multiple sclerosis: a review. DMTs, MRI, MS, PMS, RRMS
69  2021 Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series. CK, HMGCR, IMNM, SRP
70  2021 Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report. anti-HMGCR
71  2021 Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. ---
72  2021 Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis. AEs, MS, MTX, PS, RMS
73  2021 Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study. AAV, AIRD, CTD, RA
74  2021 Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients. PH-IgG, PID
75  2021 Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases. AQP4, HR, IgG, MOG, SIs
76  2021 Rituximab-induced Ileocolitis in a Patient with Gastric MALToma: A Case Report and Literature Review. MALToma
77  2021 Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia. scRNA-seq
78  2021 Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. CTD, CTD-ILD, ILD, mRSS
79  2021 SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. RBD
80  2021 Serological diagnosis of secondary syphilis in a Rituximab-treated patient: an emerging diagnostic challenge? HIV, SS, TT
81  2021 Severe infections in patients with ANCA associated vasculitis treated with rituximab. AAV
82  2021 Single Dose of Rituximab in Children with Steroid-Dependent / Frequently Relapsing Nephrotic Syndrome, Clinical Efficacy and Evaluation of Health-Related Quality of Life. FR, HRQoL, NS, SD
83  2021 Successful Pregnancies in a Patient with Childhood-onset Steroid-dependent Nephrotic Syndrome during Rituximab Maintenance Therapy. SDNS
84  2021 Systematic Review and Meta-Analysis of Rituximab for Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children. CI, NS, OR, SMD
85  2021 T cells, particularly activated CD4+ cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity. ADCC, mAb
86  2021 The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies. ---
87  2021 The effect of rituximab on the quality of life of children with refractory nephrotic syndrome. NS, QoL
88  2021 The Efficacy and Safety of Rituximab for Childhood Steroid-Dependent Nephrotic Syndrome: A Systematic Review and Meta-Analysis. RCTs, SDNS
89  2021 The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review. CS, PV
90  2021 Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study. BTZ, CIDP, CIN, CYP, INCAT-ODSS
91  2021 UK experience of ofatumumab in recurrence of focal segmental glomerulosclerosis post-kidney transplant. FSGS, OFA, SRNS
92  2021 Use of Rituximab for the Treatment of Antineutrophil Cytoplasm Antibody-associated Vasculitis in Canada, 2010-2020. AAV, ANCA, CanVasc, GPA, MPA
93  2021 Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis. EULAR, mAbs, RA, TCZ, TNF-alpha
94  2021 [State of art and new perspectives in the induction regimen of ANCA-associated vasculitis with renal involvement: from histopathology to therapy]. ANCA, CYC
95  2020 A Case Series of Patients with Isolated IgG4-related Hypophysitis Treated with Rituximab. GCs, IgG4, IgG4-RD
96  2020 A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. OCR
97  2020 A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate. ABA, ACR, ADA, BARI, IFX, IR, JAK, MTX, NMA, OR, RCTs, TCZ
98  2020 A pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis. RA
99  2020 A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE. BLM, BTZ
100  2020 Adverse electrocardiographic effects of rituximab infusion in pemphigus patients. ECG, HR, PAC, PVC